HMPL-A580 for Advanced or Metastatic Solid Tumors
This study is testing a new drug called HMPL-A580 for people with advanced or metastatic (spread to other parts of the body) solid tumors that cannot be removed by surgery. The main goals are to find a safe dose of HMPL-A580 and to see if it has any anti-tumor activity. You might be able to join if you are at least 18 years old, have a confirmed solid tumor, and have at least one tumor that can be measured. The study will look at how many participants experience side effects and how many see their tumors shrink or disappear. This study plans to enroll 186 participants.
- Study design
- This is a first-in-human, open-label study, meaning you and your doctors will know you are receiving HMPL-A580. It will involve two parts: a dose escalation phase (Part A) and a dose expansion/optimization phase (Part B).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure side effects and the maximum tolerated dose for approximately 12 months. Tumor response will be measured for at least 8 weeks up to approximately 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
At a glance
Conditions
NCT07396584
Where you'd take part
This study runs at 11 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
BRCR Global
Plantation, Floridastudy coordinator listed
Not yet recruiting
Florida Clinical Trials Group LLC (Plantation)
Plantation, Floridastudy coordinator listed
Not yet recruiting
Florida Clinical Trials Group LLC (Tamarac)
Tamarac, Floridastudy coordinator listed
Not yet recruiting
Shanghai East Hospital
Shanghai, Chinastudy coordinator listed
Recruiting
University of California Irvine Medical Center
Orange, Californiastudy coordinator listed
Not yet recruiting
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washingtonstudy coordinator listed
Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Chinano site contact published
Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Chinano site contact published
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Maximum Tolerated Dose (MTD) and/or recommended dose(s) for expansion(RDE)Approximately 12 months
To evaluate the safety, tolerability, and MTD) and/or RDE of HMPL-A580 in solid tumors
- Overview of Treatment-emergent Adverse Events (TEAEs)Approximately 12 months
To characterize the safety of HMPL-A580 at RDE(s)
- Objective Response Rate (ORR)At least 8 weeks post dose of first participant up to approximately 24 months
To characterize the tolerability, and preliminary efficacy of HMPL-A580 at RDE(s)
- Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A580Approximately 12 months
To characterize the safety, tolerability, and preliminary efficacy of HMPL-A580 at RDE(s) to determine recommended dose(s) for phase 2 dose (RP2D) or phase 3 dose (RP3D) in participants with selected solid tumors.